title: Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
authors.affiliation: PharmD, Bldg 10/Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA.
authors.forename: Yang-Min
authors.initials: YM
authors.lastname: Ning
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: Philip M
authors.initials: PM
authors.lastname: Arlen
authors.forename: Sukyung
authors.initials: S
authors.lastname: Woo
authors.forename: Seth M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: John J
authors.initials: JJ
authors.lastname: Wright
authors.forename: Howard L
authors.initials: HL
authors.lastname: Parnes
authors.forename: Jane B
authors.initials: JB
authors.lastname: Trepel
authors.forename: Min-Jung
authors.initials: MJ
authors.lastname: Lee
authors.forename: Yeong Sang
authors.initials: YS
authors.lastname: Kim
authors.forename: Haihao
authors.initials: H
authors.lastname: Sun
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: Lea
authors.initials: L
authors.lastname: Latham
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Jones
authors.forename: Clara C
authors.initials: CC
authors.lastname: Chen
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary / Q000601:surgery; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D000077143:Docetaxel; D015536:Down-Regulation; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D009919:Orchiectomy; D011241:Prednisone / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab; D013792:Thalidomide; D017430:Prostate-Specific Antigen; D011241:Prednisone